STOCK TITAN

Leap Therapeutics Inc - LPTX STOCK NEWS

Welcome to our dedicated news page for Leap Therapeutics (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Leap Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Leap Therapeutics's position in the market.

Rhea-AI Summary
Leap Therapeutics, Inc. announces a private placement of common stock and pre-funded warrants to raise approximately $40 million, extending cash runway into Q2 2026. The financing includes new and existing investors like Gilead Sciences, Inc. The proceeds will fund the expansion of the DKN-01 DeFianCe clinical trial and development program, supporting Leap's operations until Q2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
Rhea-AI Summary
Leap Therapeutics, Inc. (LPTX) reported financial results for Q4 and year-end 2023, highlighting new clinical data from Phase 2 studies on DKN-01 in colorectal and gastroesophageal cancers. The company showcased a 30% overall response rate and 93% disease control rate in CRC patients. Enrollment completion in the DisTinGuish study sets the stage for delivering randomized controlled data in 2024. Financially, the company reported a net loss of $81.4 million for 2023, with increased research and development expenses compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced positive clinical data from the DeFianCe study, showing a 30% objective response rate (ORR) and 93% disease control rate (DCR) in second-line colorectal cancer (CRC) patients treated with DKN-01 plus bevacizumab and chemotherapy. The study revealed the greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients, with a 46% ORR, 100% DCR, and a preliminary median progression-free survival (PFS) of 9.4 months. The company plans to report additional clinical data and subgroup analyses in a conference call on January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
conferences clinical trial
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) to Present Corporate Overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
conferences
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) completes enrollment in Part C of the DisTinGuish study evaluating DKN-01, their anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.67%
Tags
none
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) will present new data from the DeFianCe study at the 2024 ASCO Gastrointestinal Cancers Symposium, evaluating DKN-01, an anti-DKK1 antibody, in combination with bevacizumab and chemotherapy for advanced colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
conferences
Rhea-AI Summary
Leap Therapeutics, Inc. (LPTX) President and CEO, Douglas E. Onsi, to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.87%
Tags
conferences
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) Reports Q3 Financial Results and Development Updates for DKN-01 in Colorectal and Gastric Cancer Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
-
Rhea-AI Summary
Leap Therapeutics to participate in two investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
conferences
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported financial results for the second quarter ended June 30, 2023. The company announced positive data from Phase 2 studies of DKN-01 in treating colorectal and gastric cancer, leading to the initiation of randomized controlled trials. The company also presented long-term follow-up data at the 2023 ASCO Annual Meeting, demonstrating promising results. Financially, the company's net loss decreased to $13.4 million in the second quarter of 2023, compared to $17.0 million for the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
Leap Therapeutics Inc

Nasdaq:LPTX

LPTX Rankings

LPTX Stock Data

82.96M
24.77M
2.96%
30.37%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About LPTX

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.